Acinetobacter Baumannii Nosocomial Infections
Languages of publication
Nosocomial infections caused by strains Acinetobacter baumannii strands are a growing clinical problem. The occurrence of multidrug-resistant strands is observed and that limits the ways of therapy considerably. The aim of the study was to determine the rate of infection and susceptibility spectrum of the species Acinetobacter baumannii isolated from patients treated at Maria Skłodowska-Curie Memorial Hospital in Zgierz with particular emphasis on surgical wards. Materials and methods. The material consisted of Acinetobacter baumannii isolates were obtained from samples of materials from patients treated at Maria Skłodowska-Curie Memorial Hospital in Zgierz from January to December 2011. Isolated bacterial strains were cultured at microbiological substrates. Isolates were identified to species using the VITEK 2 GN card (bioMérieux) and Vitek 2 automated system (bioMérieux). Susceptibility towards antibiotics of particular strains was determined by the means of AST NO 93 card. In the case of resistance towards carbapenem, the MIC was marked by E-test with Mueller Hinton substrate. The occurrence of MBL was verified by the means of disc system with Mueller Hinton substrate. Results. We have shown that total number of Acinetobacter baumannii infections at hospital was 140 (10,31% of total results of cultures). Percentage of Acinetobacter baumannii infections at wards: Intensive Care Unit 48%, Surgical Departments 20%, Internal Diseases Department 16%, Neurology 13%, other wards - 3%. The susceptibility percentage of Acinetobacter Baumannii against antibiotics: colistin 90%, imipenem 64%, meropenem 43%, ampicillin-sulbactam 28%, amikacin 27%, gentamicin 24%, cefepime 9%, ceftazidime 7%, ciprofloxacin 7% Conclusions. Acinetobacter baumannii infections are a significant proportion of nosocomial infections. Most relate to surgical wards and ICUs. Acinetobacter baumannii is resistant against most antibiotics. The highest percentage of sensitivity demonstrated for colistin and carbapenems
1 - 09 - 2013
15 - 10 - 2013
- 1. Karlowsky JA, Draghi DC, Jones ME et al.: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 Antimicrobial Agents and Chemotherapy 2003: 47; 1681-88.
- 2. Peleg AY , Seifert H, Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clinical Microbiology Reviews 2008; 21: 538-82.[PubMed][WoS]
- 3. Lee K, Yong D, Jeong SH et al.: Multidrug- Resistant Acinetobacter spp.: Increasingly Problematic Nosocomial Pathogens Yonsei. Medical J 2011; 52: 879-91.[WoS]
- 4. Jawad A, Seifert H, Snelling AM et al.: Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates. J ClinicalMicrobiol 1998; 36: 1938-41.
- 5. Wendt C, Dietze B, Dietz E et al.: Survival of Acinetobacter baumannii on dry surfaces. J ClinicalMicrobiol 1997; 35: 1394-97.[PubMed]
- 6. Marti S, Chabane YN , Alexandre S et al.: Growth of Acinetobacter baumannii in Pellicle Enhanced the Expression of Potential Virulence Factors Plos One 2011; 6.
- 7. Husni RN , Goldstein LS, Arroliga AC et al.: Risk factors for an outbreak of multi-drug-resistant acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115: 1378-82.[Crossref]
- 8. Falagas ME, Bliziotis IA , Siempos II : Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. CriticalCare 2006; 10.
- 9. Falagas ME, Rafailidis PI: Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care 2007; 11.
- 10. Falagas ME, Koletsi PK, Bliziotis IA : The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J MedicalMicrobiol 2006; 55: 1619-29.[PubMed]
- 11. O’Shea MK: Acinetobacter in modern warfare. International J Antimicrobiol Agents 2012; 39: 363-75.
- 12. Kempf M, Rolain JM: Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. International J Antimicrobiol Agents 2012; 39: 105-14.
- 13. BergogneBerezin E, Towner KJ: Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features. ClinicalMicrobiol Reviews 1996; 9: 148.
- 14. Unal S, Garcia-Rodriguez JA: Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagnostic Microbioland Infectious Dis 2005; 53: 265-71.
- 15. Mera RM, Miller LA, Amrine-Madsen H et al.: Acinetobacter baumannii 2002-2008: Increase of Carbapenem-Associated Multiclass Resistance in the United States Microbial Drug Resistance 2010; 16: 209-15.
- 16. Queenan AM, Pillar CM, Deane J et al.: Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diag Microbiol andInfectious Dis 2012; 73: 267-70.
- 17. Li C, Kuti JL, Nightingale CH et al.: Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. JClinical Pharmacol 2006; 46: 1171-78.
- 18. Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents and Chemother 2005; 49: 1337-39.[PubMed]
- 19. Kipnis E, Guery BP: Colistin revisited. Antibiotiques 2010; 12: 205-27.[Crossref][WoS]
- 20. Michalopoulos AS , Falagas ME: Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1: 30.
- 21. Hancock REW , Chapple DS: Peptide antibiotics. Antimicrob Agents and Chemother 1999; 43: 1317-23.[PubMed]
- 22. Landman D, Georgescu C, Martin DA et al.: Polymyxins revisited. Clinical Microbiol Reviews 2008; 21: 449-65.
- 23. Kalin G, Alp E, Coskun R et al.: Use of highdose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infection and Chemother 2012; 18: 872-77.
- 24. Livermore DM, Hill RLR, Thomson H et al.: Antimicrobial treatment and clinical outcome for infections with carbapenem-and multiply-resistant Acinetobacter baumannii around London. International J Antimicrobial Agents 2010; 35: 19-24.
- 25. Brauers J, Frank U, Kresken M et al.: Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clinical Microbiol and Infection 2005; 11: 24-30.
- 26. Bantar C, Fernandez Canigia L, AlejandraBerger M et al.: Pharmacodynamic Assessment of Amoxicillin-Sulbactam Against Acinetobacter baumannii: Searching the Optimal Dose and Infusion Time Through a Human ex-vivo Model. BrazilianJ Infectious Dis 2009; 13: 348-52.[WoS]
- 27. Deveci A, Coban AY , Acicbe O et al.: In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother 2012; 24: 247-52.[PubMed]
- 28. Patzer J, Dzierzanowska D, Turner P: Susceptibility patterns of Gram-negative bacteria from a Polish intensive care unit, 1997-2000. InternationalJ Antimicrob Agents 2002; 19: 431-34.
- 29. Eckmann C, Heizmann WR , Leitner E et al.: Prospective, Non-Interventional, Multi-Centre Trial of Tigecycline in the Treatment of Severely Ill Patients with Complicated Infections - New Insights into Clinical Results and Treatment Practice Chemotherapy 2011; 57: 275-84.[PubMed]
- 30. Ricciardi R, Ricciardi AM, Danzi G: In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 2009; 17: 236-39.
Publication order reference